Clinical course of recurrent respiratory papillomatosis: Comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11

Head & Neck ◽  
2014 ◽  
Vol 37 (11) ◽  
pp. 1625-1632 ◽  
Author(s):  
Robin E. A. Tjon Pian Gi ◽  
Michel R. M. San Giorgi ◽  
Lorian Slagter-Menkema ◽  
Bettien M. van Hemel ◽  
Bernard F. A. M. van der Laan ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Clinical Course ◽  
Recurrent Respiratory Papillomatosis

Identification of 11 Different HPV Subtypes in Adult Patients With Recurrent Respiratory Papillomatosis

2020 ◽  
Vol 163 (4) ◽  
pp. 785-790
Author(s):  
Rebecca C. Hoesli ◽  
Melissa L. Wingo ◽  
Brent E. Richardson ◽  
Robert W. Bastian
Keyword(s):  
Human Papillomavirus ◽  
Patient Outcomes ◽  
Clinical Course ◽  
Adult Population ◽  
Tertiary Care ◽  
Recurrent Respiratory Papillomatosis ◽  
Definition Of ◽  
Large Adult

Objective To define the human papillomavirus (HPV) subtypes seen in a large adult population with traditionally defined recurrent respiratory papillomatosis. Study Design Retrospective review. Setting Tertiary care laryngology practice. Subjects and Methods All patients had a firm diagnosis of recurrent respiratory papillomatosis defined by (1) visually obvious papillomas, (2) recurrence requiring multiple surgeries, and (3) pathology diagnosis of “papilloma.” Each patient had also undergone HPV subtyping. Age, sex, presence of malignancy, and HPV subtypes were tabulated and correlated with long-term patient outcomes. Results A total of 184 patients were identified who fulfilled the above criteria. In total, 87.0% (160) had a low risk subtype; 9.2% had an alternative subtype. These consisted of subtypes 16, 18, 31, 44, 45, 55, and 70. Four patients (2.2%) had combinations of subtypes, with 1 patient with HPV 11 and 16, 1 patient with HPV 11 and 76, 1 patient with 11 and 84, and 1 patient with 18 and 45. Finally, 3.8% of patients were HPV negative, despite fulfilling all 3 criteria listed above. Conclusion In the patient population above, almost 10% of patients had an HPV subtype other than 6 and 11. This suggests that traditionally defined recurrent respiratory papillomatosis (RRP) can be caused by HPV subtypes other than 6 and/or 11. In addition, the clinical course of persons with this definition of RRP appears to vary by subtype, and this information may offer the ability to nuance follow-up instructions, reducing in particular the burden placed upon patients who have RRP caused by subtypes 6 and 11.

Human Papillomavirus-11-associated Recurrent Respiratory Papillomatosis is more Aggressive than Human Papillomavirus-6-associated Disease

2001 ◽  
Vol 4 (1) ◽  
pp. 68-72 ◽  
Author(s):  
R. Rabah ◽  
W.D. Lancaster ◽  
R. Thomas ◽  
L. Gregoire
Keyword(s):  
Polymerase Chain Reaction ◽  
Squamous Cell Carcinoma ◽  
African American ◽  
Human Papillomavirus ◽  
Clinical Course ◽  
Recurrent Respiratory Papillomatosis ◽  
Chain Reaction ◽  
Younger Age ◽  
Polymerase Chain ◽  
Active Disease

The aim of this study was to determine whether viral type (HPV-6 vs. HPV-11) could predict the clinical course of recurrent respiratory papillomatosis in children. Viral typing, using the polymerase chain reaction, was performed on laryngeal biopsies of 61 patients treated at Children's Hospital of Michigan. HPV-6 was detected in 29 of the patients' biopsies and HPV-11 in 32 biopsies. HPV-11 was more common among the African-American patients than among Caucasians ( P = 0.001). Patients with HPV-11 were diagnosed at a younger age (36.2 vs. 48.2 months; P = 0.04) and were more likely to have active disease ( P = 0.0311) at the time of this study. They tended to have longer periods of disease activity (8 years vs. 5 years; P = 0.026), required more surgical procedures (42 procedures/patient vs. 13.6; P = 0.02), and more procedures per patient, per year (2.9 vs. 5.3; P = 0.0164). Three of the patients infected with HPV-11 developed invasive papillomatosis and bronchogenic squamous cell carcinoma, and two of these patients died of disease. Our findings suggest that HPV-11 infection confers a more aggressive course to recurrent respiratory papillomatosis.

The Impact of Laryngopharyngeal Reflux on Occurrence and Clinical Course of Recurrent Respiratory Papillomatosis

2021 ◽  
Author(s):  
Daša Gluvajić ◽  
Maja Šereg‐Bahar ◽  
Aleš Jerin ◽  
Rado Janša ◽  
Irena Hočevar‐Boltežar
Keyword(s):  
Clinical Course ◽  
Laryngopharyngeal Reflux ◽  
Recurrent Respiratory Papillomatosis ◽  
The Impact

scholarly journals Differences in Transcriptional Activity of Human Papillomavirus Type 6 Molecular Variants in Recurrent Respiratory Papillomatosis

PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132325 ◽  
Author(s):  
Caroline Measso do Bonfim ◽  
João Simão Sobrinho ◽  
Rodrigo Lacerda Nogueira ◽  
Daniel Salgado Kupper ◽  
Fabiana Cardoso Pereira Valera ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Transcriptional Activity ◽  
Recurrent Respiratory Papillomatosis ◽  
Molecular Variants

Multi‐Year Effect of Human Papillomavirus Vaccination on Recurrent Respiratory Papillomatosis

2019 ◽  
Vol 130 (2) ◽  
pp. 442-447 ◽  
Author(s):  
Hiroumi Matsuzaki ◽  
Kiyoshi Makiyama ◽  
Ryoji Hirai ◽  
Hirotaka Suzuki ◽  
Ryohei Asai ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Recurrent Respiratory Papillomatosis ◽  
Human Papillomavirus Vaccination ◽  
Year Effect

2′,5′-Oligoadenylate synthetase activity analysis and human papilloma virus typing as prognostic factors in patients with recurrent respiratory papillomatosis

2004 ◽  
Vol 118 (10) ◽  
pp. 750-756 ◽  
Author(s):  
V. Gerein ◽  
E. Rastorguev ◽  
J. Gerein ◽  
E. Lodemann ◽  
H. Pfister ◽  
...  
Keyword(s):  
Human Papilloma Virus ◽  
Interferon Alpha ◽  
Clinical Course ◽  
Recurrent Respiratory Papillomatosis ◽  
Synthetase Activity ◽  
Oligoadenylate Synthetase ◽  
Papilloma Virus ◽  
Interferon Alpha Therapy ◽  
Alpha Therapy

Objective: Determination of early prognostic factors in patients with recurrent respiratory papillomatosis is extremely important, so the major goal of our prospective, multicentre study was to evaluate (1) the feasibility of various factors to determine prognosis of the clinical course,as well as (2) the response to interferon-alpha therapy in recurrent respiratory papillomatosis. Methods: Forty-two patients with recurrent respiratory papillomatosis were treated with interferon-alpha (3 MU/m2 three times per week; mean therapy duration was 2.7 ± 1.8 years)in 1983–1994 and followed-up until 2003. Human papilloma virus (HPV) type, recurrent respiratory papillomatosis severity and 2′,5′-oligoadenylate synthetase activity were determined by standard methods and analysed for correlation with the results of long-term clinical outcome.Results and conclusion: Patients with HPV type 11, a severity score >4, a high number of surgical procedures prior to interferon-alpha therapy and a high basal 2′,5′-oligoadenylate synthetase activity should be considered at high risk of an aggressive clinical course, often with spread to lower airway passages, malignant transformation and death. Human papilloma virus type, score for recurrent respiratory papillomatosis severity, number of surgical procedures and 2′,5′-oligoadenylate synthetase activity showed significant association with response to interferon-alpha therapy and the long-term clinical course, so these factors have value in predicting prognosis in recurrent respiratory papillomatosis.

Molecular subtypification of human papillomavirus in male adult individuals with recurrent respiratory papillomatosis

2015 ◽  
Vol 42 (5) ◽  
pp. 385-389 ◽  
Author(s):  
Carmen S. García-Romero ◽  
Matsuharu Akaki-Caballero ◽  
Ana G. Saavedra-Mendoza ◽  
Ana K. Guzmán-Romero ◽  
Patricia Canto ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Recurrent Respiratory Papillomatosis ◽  
Male Adult
Sign in / Sign up

Export Citation Format

Share Document